Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Company Overview - Coya Therapeutics, Inc. (NASDAQ: COYA) is a US biotech company focused on neurodegenerative and autoimmune diseases through T cell (Treg) modulation [1] - The company's main candidates are COYA 302 and COYA 301, with COYA 302 being the most promising for multiple indications [1] Analyst Background - The article includes a brief background of Myriam Hernandez Alvarez, who holds degrees in Electronics and Telecommunication Engineering, Computer Science, Business Management, and a Ph.D. in Computer Applications [1]